Advertisement
Advertisement

NRXP

NRXP logo

NRX Pharmaceuticals, Inc. Common Stock

2.55
USD
Sponsored
+0.04
+1.59%
Apr 17, 16:00 UTC -4
Closed
exchange

After-Market

2.54

-0.01
-0.39%

NRXP Earnings Reports

Positive Surprise Ratio

NRXP beat 7 of 15 last estimates.

47%

Next Report

Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$14.54M
/
-$0.04
Implied change from Q4 25 (Revenue/ EPS)
+1378.64%
/
+300.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/
-80.95%

NRX Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Mar 23, 2026, NRXP reported earnings of -0.01 USD per share (EPS) for Q4 25, missing the estimate of 0.00 USD, resulting in a -361.54% surprise. Revenue reached 983.00 thousand, compared to an expected 7.68 million, with a -87.19% difference. The market reacted with a -6.25% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 14.54 million USD, implying an increase of 300.00% EPS, and increase of 1378.64% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Evotec SE - ADR
Report Date
Apr 08, 2026 For Q4 25
Estimate
$0.31
Actual
$0.08
Surprise
-74.45%
logo
Vivos Therapeutics, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$0.49
Actual
-$0.57
Surprise
-17.65%
logo
Traws Pharma, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.24
Actual
$0.63
Surprise
+150.46%
logo
Cosmos Holdings Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.31
Surprise
-659.80%
logo
BIOMERICA INC
Report Date
Apr 13, 2026 For Q3 26
Estimate
-
Actual
-$0.44
Surprise
-
FAQ
For Q4 2025, NRX Pharmaceuticals, Inc. Common Stock reported EPS of -$0.01, missing estimates by -361.54%, and revenue of $983.00K, -87.19% below expectations.
The stock price moved down -6.25%, changed from $2.08 before the earnings release to $1.95 the day after.
The next earning report is scheduled for May 13, 2026.
Based on 6 analysts, NRX Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.04 and revenue of $14.54M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement